Title: Stangier J, et al. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008 Dec;48(12):1411-9.
1408238-40-3
211915-84-3
211915-06-9
1246817-44-6
1422435-41-3
1408238-37-8
25501-08-0 | 5-Aza-2'-deoxyuridine | AA00C2XB | MFCD30720475
219121-67-2 | 3-(1H-Imidazol-4-yl)pyridine Dihydrochloride | AA00C347 | MFCD06797679
243972-30-7 | 6-THIOPHEN-2-YL-1H-INDOLE | AA00C3BE | MFCD04114748
21639-28-1 | 2-(Methylamino)benzenesulfonamide | AA00C3S9 | MFCD11040243
219312-44-4 | 5-Chloro-2-methyl-3-nitroaniline | AA00C42N | MFCD01109853
2159-40-2 | 2-(4-Bromobenzoyl)benzoic acid | AA00C4GH | MFCD00559266
38460-08-1 | 1-(2-Chloroethyl)-3,5-dimethyl-1h-pyrazole | AA00C593 | MFCD00215355
362049-55-6 | D-PHENYL-D5-ALANINE | AA00C5EV | MFCD01861577
36475-47-5 | 3-Methylhistamine dihydrochloride | AA00C5KZ | MFCD00037002
336195-37-0 | 4-((2,5-Dichlorophenyl)sulfonyl)butan-2-one | AA00C5QM | MFCD00450449